The transaction includes an upfront payment of $20 million and additional contingent payments of up to $25 million tied to regulatory and commercial milestones, including FDA clearance of the company’s next-generation robotic technology.
Rouen, France–based Robocath develops robotic technologies for interventional cardiology and neurointerventions. The company holds CE mark and other regulatory approvals for its first robotic solution, the R-One system, currently used in Europe, Africa and China. It launched a first-in-human study for the second-generation robotic system in January.
The company’s next-generation technology integrates capabilities designed to meet the increasing demands of complex coronary procedures. It develops robotic solutions that utilize bionic technology aimed at optimizing the safety of robotic-assisted coronary angioplasty.
Robocath’s procedure revascularizes the cardiac muscle through the implantation of one or more stents to arteries supplying blood. It designed its robotic technologies to operate with precision and perform accurate movements to create better interventional conditions. The platform enables the simultaneous manipulation of up to five interventional devices.
(Learn more about the surgical robotics space in our MassDevice Surgical Robotics Special Report. Download the report for free here.)
More about what Robocath brings to Stereotaxis
Stereotaxis says the acquisition significantly strengthens its position as “a leading platform for the full spectrum of endovascular procedures.” It combines complementary technologies to deliver next-generation, fully integrated robotic solutions. The company expects to deliver offerings for electrophysiology, interventional cardiology and neurointerventions.
The portfolio at Stereotaxis already includes surgical robotic technology, with the next-generation magnetic GenesisX surgical robot. It’s vying for a place in the endovascular robotic space that includes Microbot Medical, XCath, Remedy Robotics and Sentante.
According to the company, the combination of its magnetic navigation technology with Robocath’s mechanical robotic system creates a differentiated, fully robotic solution for endovascular surgery.
Stereotaxis uses precise, computer-controlled magnetic fields to enable navigation of the distal tip of interventional devices. Robocath’s platform offers multi-device control at the bedside. Together, the companies expect a synergistic approach to improving procedural precision, efficiency and outcomes.
Plans for the future
Stereotaxis plans to accelerate the development of the next-generation Robocath system and pursue regulatory submissions in the U.S. and Europe in the next two years. It also intends to enhance Robocath’s system with proprietary hardware and software. The company hopes to enable operating room integration, automation and remote procedures.
Combining solutions could provide a seamless joint offering in interventional cardiology and neurointerventions initially. Then, the company plans to expand into electrophysiology.
Stereotaxis expects approximately $2 million in revenue from Robocath in the first year post-acquisition. It anticipates the acquisition to become breakeven by the third year. The company agreed to pay the deal’s consideration in cash or common stock. It anticipates a mid-2026 close, at which point Robocath will operate as a wholly owned subsidiary.
Commentary from company officials
David Fischel, Stereotaxis chair and CEO, said:
“Robocath represents a highly strategic addition to Stereotaxis, amplifying and accelerating our strategy as the leading robotic platform for the broad spectrum of endovascular procedures. By combining our complementary robotic mechanisms, we are creating a uniquely capable platform that expands our reach across interventional medicine. This transaction accelerates our strategy, enhances our technological leadership, provides attractive commercial synergies, opens new avenues for growth, and supports other strategic opportunities being pursued by Stereotaxis.
“We are delighted to welcome the accomplished Robocath team to Stereotaxis. This acquisition is a reflection of our commitment to technological leadership across endovascular robotics, with continued investment in significant innovations that improve access, efficiency, and outcomes of minimally-invasive cardiovascular and neurovascular therapies.”
Philippe Bencteux, Robocath founder and CEO, said:
“For over fifteen years, we have been committed to pioneering the most sophisticated plug-and-play bionic robotic technology for endovascular procedures. Joining Stereotaxis provides the scale, complementary technologies, and strategic alignment needed to accelerate our development and expand our impact. We believe this combination will unlock significant opportunities in rapidly growing markets, which are becoming increasingly receptive to robotics.”
